Biotech · Private company
Orion Corporation, Orion Pharma
Track this companyFree. Adds Orion Corporation, Orion Pharma to your Dealase workspace and tells you when its record changes.
Clinical trials84 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- LevosimendanPhase 3 · Amyotrophic Lateral SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Gemcitabine and nab-paclitaxelPhase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- Ipilimumab and nivolumabPhase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- MidazolamPhase 2 · Prostate Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- ODM-208Phase 2 · Prostate Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- ODM-212Phase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- ODM-212Phase 2 · Solid TumoursClinicalTrials.gov · fetched Nov 12, 2026
- sotorasibPhase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- A 2-part Phase 1/2 Open-label Trial on ODM-212PHASE1_PHASE2 · RECRUITING · started Mar 27, 2026ClinicalTrials.gov NCT07563738 · fetched Nov 12, 2026
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 20, 2024ClinicalTrials.gov NCT06353386 · fetched Nov 12, 2026
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid TumoursPHASE1_PHASE2 · RECRUITING · started Oct 26, 2023ClinicalTrials.gov NCT06725758 · fetched Nov 12, 2026
- Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label ExtensionPHASE3 · TERMINATED · started Jun 26, 2019ClinicalTrials.gov NCT03948178 · fetched Nov 12, 2026
- Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALSPHASE3 · COMPLETED · started Jun 21, 2018ClinicalTrials.gov NCT03505021 · fetched Nov 12, 2026
- Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 19, 2018ClinicalTrials.gov NCT03436485 · fetched Nov 12, 2026
- Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerPHASE3 · COMPLETED · started Nov 30, 2016ClinicalTrials.gov NCT02799602 · fetched Nov 12, 2026
- Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerPHASE3 · COMPLETED · started Sep 12, 2014ClinicalTrials.gov NCT02200614 · fetched Nov 12, 2026